...extended to sense other tumor suppressors or oncogenes. Aprea Therapeutics AB, City of Hope and MultiVir Inc....
...p53 deficient cells.” Nature Communications (2017) Michael Leviten, Senior Writer Aprea Therapeutics AB City of Hope Dresden University of Technology MultiVir Inc. Tumor...

...Therapeutics AB has the chaperone-like compound APR-246 in Phase II testing for ovarian cancer, and MultiVir Inc....
...MRC), London, U.K. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Mission Therapeutics Ltd., Cambridge, U.K. MultiVir Inc....

...Online Intelligence; company websites Target Modality Companies/Institutions Technology description Phase of development p53 Gene therapy MultiVir Inc....
...venture rounds for a Scandinavian biotech. Other strategies involve using gene therapy to restore p53. MultiVir...
...Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Kyras Therapeutics Inc., New York, N.Y. MultiVir Inc....

...Ltd. , Etubics Corp. , GenVec Inc. , Milo Biotechnology LLC , Momotaro-Gene Inc. , MultiVir Inc....

...Date announced: 2015-05-27 Type: IPO Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald; LifeSci Capital Note: MultiVir...

...million Price: $12-$14 Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald; LifeSci Capital Overallotment: 690,000 Note: MultiVir...

...to $70 million Shares: TBD Price: TBD Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald Note: MultiVir...

...3/31/15 Up to $57.5M Ph II CoLucid Pharmaceuticals Inc. 3/30/15 Up to $86.3M Ph III MultiVir Inc....